Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

Clinical and Vaccine Immunology

Volumn 17, Issue 6, 2010, Pages 1017-1026

  Esposito, Susanna ^a   Tansey, Susan ^b   Thompson, Allison ^c   Razmpour, Ahmad ^c   Liang, John ^c   Jones, Thomas R ^c   Ferrera, Giuseppe ^d   Maida, Alessandro ^e   Bona, Gianni ^f   Sabatini, Caterina ^a   Pugni, Lorenza ^a   Emini, Emilio A ^c   Gruber, William C ^c   Scott, Daniel A ^c   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER INC   (United States)

^d Ragusa Hospital   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

13 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIPNEUMOCOCCAL OPSONOPHAGOCYTIC ASSAY; ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEDIATRICS; PERTUSSIS; PHASE 3 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SIDE EFFECT; SLEEP; TETANUS; TODDLER; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFANT; ITALY; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; TREATMENT OUTCOME; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 77953156443     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00062-10     Document Type: Article

References (45)

1. Bender, J. M., K. Ampofo, K. Korgenski, J. Daly, A. T. Pavia, E. O. Mason, and C. L. Byington. 2008. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin. Infect. Dis. 46:1346-1352.
2. Black, S. B., C. O. Cimino, J. Hansen, E. Lewis, P. Ray, B. Corsaro, J. Graepel, and D. Laufer. 2006. Immunogenicity and safety of measles-mumps- rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 25:306-311.
3. Byington, C. L., M. H. Samore, G. J. Stoddard, S. Barlow, J. Daly, K. Korgenski, S. Firth, D. Glover, J. Jensen, E. O. Mason, C. K. Shutt, and A. T. Pavia. 2005. Temporal trends of invasive disease due to Streptococcus pneumoniae in the intermountain west: emergence of nonvaccine groups. Clin. Infect. Dis. 41:21-29.
4. Centers for Disease Control and Prevention. 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb. Mortal. Wkly. Rep. 54:893-897.
5. Centers for Disease Control and Prevention. 2008. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb. Mortal. Wkly. Rep. 57:144-148.
6. Concepcion, N. F., and C. E. Frasch. 2001. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal- polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272.
7. Dagan, R., and K. L. O'Brien. 2005. Modeling the association between pneumococcal carriage and child-care center attendance. Clin. Infect. Dis. 40:1223-1226.
8. Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Käyhty, P. Karma, R. Kohberger, G. Siber, P. H. Mäkelä, and the Finnish Otitis Media Study Group. 2001. Efficacy of pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
9. Esposito, S., A. Lizioli, A. Lastrico, E. Begliatti, A. Rognoni, C. Tagliabue, L. Cesati, V. Carreri, and N. Principi. 2007. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Respir. Res. 8:12.
10. Esposito, S., L. Pugni, S. Bosis, A. Proto, L. Cesati, C. Bianchi, C. Cimino, F. Mosca, and N. Principi. 2005. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 2, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 23:1703-1708.
11. Feavers, I., I. Knezevic, M. Powell, and E. Griffiths on behalf of the WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. 2009. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 27:3681-3688.
12. Goldblatt, D., J. Southern, L. Ashton, P. Richmond, P. Burbidge, J. Tasevska, A. Crowley-Luke, N. Andrews, R. Morris, R. Borrow, K. Cartwright, and E. Miller. 2006. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25:312-319.
13. Haber, M., A. Barskey, W. Baughman, L. Barker, C. G. Whitney, K. M. Shaw, W. Orenstein, and D. S. Stephens. 2007. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25:5390-5398.
14. Hansen, J., S. Black, H. Shinefield, T. Cherian, J. Benson, B. Fireman, E. Lewis, P. Ray, and J. Lee. 2006. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr. Infect. Dis. J. 25:779-781.
15. Hausdorff, W. P. 2007. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 25:2406-2412.
16. Hicks, L. A., L. H. Harrison, B. Flannery, J. L. Hadler, W. Schaffner, A. S. Craig, D. Jackson, A. Thomas, B. Beall, R. Lynfield, A. Reingold, M. M. Farley, and C. G. Whitney. 2007. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196:1346-1354.
17. Hu, B. T., X. Yu, T. R. Jones, C. Kirch, S. Harris, S. W. Hildreth, D. V. Madore, and S. A. Quataert. 2005. Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin. Diagn. Lab. Immunol. 12:287-295.
18. Hughes, J.Y., M.D. Snape, C.L. Klinger, E. Daniels, H. Laytone, L. Rollinson, S. Pestridge, E. Dymond, E. Galiza, D.A. Scott, S. Patterson, W.C. Gruber, L.M. Yu, S.N. Faust, A. Finn, P.T. Heath, and A.J. Pollard. 2009. Immunogenicity of booster doses of 13-valent pneumococcal conjugate and Hib/MenC vaccines given at 12 months of age in the UK. ESPID 2009 - 27th European Society for Paediatric Infectious Diseases Annual Meeting, Brussels, Belgium, 9-12 June 2009.
19. Käyhty, H., H. Ahman, K. Eriksson, M. Sörberg, and L. Nilsson. 2005. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5, and 12 months of age. Pediatr. Infect. Dis. J. 24:108-114.
20. Knuf, M., P. Habermehl, C. Cimino, G. Petersen, and H. J. Schmitt. 2006. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24:4727-4736.
21. Knuf, M., L. Szenborn, M. Moro, C. Petit, N. Bermal, L. Bernard, I. Dieussaert, and L. Schuerman. 2009. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr. Infect. Dis. J. 28:S97-S108.
22. Messina, A. F., K. Katz-Gaynor, T. Barton, N. Ahmad, F. Ghaffar, D. Rasko, and G. H. McCracken, Jr. 2007. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J. 26:461-467.
23. Millar, E. V., K. L. O'Brien, J. P. Watt, M. A. Bronsdon, J. Dallas, C. G. Whitney, R. Reid, and M. Santosham. 2006. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin. Infect. Dis. 43:8-15.
24. Millar, E. V., J. P. Watt, M. A. Bronsdon, J. Dallas, R. Reid, M. Santosham, and K. L. O'Brien. 2008. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin. Infect. Dis. 47:989-996.
25. Miyamura, K., S. Nishio, A. Ito, R. Murata, and R. Kono. 1974. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. J. Biol. Stand. 2:189-201.
26. Moore, M. R., R. E. Gertz, Jr., R. L. Woodbury, G. A. Barkocy-Gallagher, W. Schaffner, C. Lexau, K. Gershman, A. Reingold, M. Farley, L. H. Harrison, J. L. Hadler, N. M. Bennett, A. R. Thomas, L. McGee, T. Pilishvili, A. B. Brueggemann, C. G. Whitney, J. H. Jorgensen, and B. Beall. 2008. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197:1016-1027.
27. O'Brien, K. L., E. V. Millar, E. R. Zell, M. Bronsdon, R. Weatherholtz, R. Reid, J. Becenti, S. Kvamme, C. G. Whitney, and M. Santosham. 2007. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196:1211-1220.
28. Olivier, C., B. H. Belohradsky, S. Stojanov, E. Bonnet, G. Petersen, and J. G. Liese. 2008. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine 26:3142-3152.
29. Ongkasuwan, J., T. A. Valdez, K. G. Hulten, E. O. Mason, Jr., and S. L. Kaplan. 2008. Pneumococcal mastoiditis in children and the emergence of multidrug-resistance serotype 19A isolates. Pediatrics 122:34-39.
30. Paradiso, P. R., D. A. Hogerman, D. V. Madore, H. Keyserling, J. King, K. S. Reisinger, M. M. Blatter, E. Rothstein, H. H. Bernstein, and J. Hackell. 1993. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b in young infants. Pediatrics 92:827-832.
31. Philips, D. C., J. West, R. Eby, M. Koster, D. V. Madore, and S. Q. Quataert. 1990. An ELISA employing an Haemophilus influenzae type b oligosaccharide human serum albumin conjugate correlates with the radioantigen binding assay. J. Immunol. Methods 135:121-128.
32. Poehling, K. A., T. R. Talbot, M. R. Griffin, A. S. Craig, C. G. Whitney, E. Zell, C. A. Lexau, A. R. Thomas, L. H. Harrison, A. L. Reingold, J. L. Hadler, M. M. Farley, B. J. Anderson, and W. Schaffner. 2006. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295:1668-1674.
33. Quataert, S. A., C. S. Kirch, L. J. Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590-597.
34. Quataert, S., D. Martin, P. Anderson, G. S. Giebink, J. Henrichsen, M. Leinonen, D. M. Granoff, H. Russell, G. Siber, H. Faden, D. Barnes, and D. V. Madore. 2001. A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol. Invest. 30:191-207.
35. Quataert, S. A., K. Rittenhouse-Olson, C. S. Kirch, B. Hu, S. Secor, N. Strong, and D. V. Madore. 2004. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin. Diagn. Lab. Immunol. 11:1064-1069.
36. Schmitt, H. J., J. Faber, I. Lorenz, B. Schmöle-Thoma, and N. Ahlers. 2003. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 21:3653-3662.
37. Scott, D., J. Ruckle, M. Dar, S. Baker, H. Kondoh, and S. Lockhart. 2008. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr. Int. 50:295-299.
38. Talbot, T. R., K. A. Poehling, T. V. Hartert, P. G. Arbogast, N. B. Halasa, E. Mitchel, W. Schaffner, A. S. Craig, K. M. Edwards, and M. R. Griffin. 2004. Elimination of racial difference in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr. Infect. Dis. J. 23:726-731.
39. Tan, T. Q., E. O. Mason, Jr., R. E. Wald, W. J. Barson, G. E. Schutze, J. S. Bradley, L. B. Givner, R. Yogev, K. S. Kim, and S. L. Kaplan. 2002. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics 110:1-6.
40. Vesikari, T., J. Wysocki, B. Chevallier, A. Karvonen, H. Czajka, J. P. Arsène, P. Lommel, I. Dieussaert, and L. Schuerman. 2009. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr. Infect. Dis. J. 28:S66-S76.
41. Vestrheim, D. F., O. Løvoll, I. S. Aaberge, D. A. Caugant, E. A. Høiby, H. Bakke, and M. R. Bergsaker. 2008. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26:3277-3281.
42. Wernette, C. M., C. E. Frasch, D. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S. A. Quataert, S. Hildreth, D. J. Sikkema, H. Käyhty, I. Jonsdottir, and M. H. Nahm. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10:514-519.
43. World Health Organization. 2007. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly. Epidemiol. Rec. 82:93-104.
44. World Health Organization. 2005. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech. Rep. Ser. 927:64-98.
45. Zhou, F., A. Shefer, Y. Kong, and J. P. Nuorti. 2008. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121:253-260.